Skip to content
Screener

Total Revenue at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$989.71M+19.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$214M+28.1%
RFL
Rafael Holdings, Inc.RFL
$179K-50.6%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$58.82M+10.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$92.1M+28.7%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$17.7M+15.0%

Segments

By product

See full
MIPLYFFA$30.2M+40.5%
OLPRUVA$200K-33.3%

By segment

See full
Reportable Segment$39.66M+53.3%

Other financials

Income statement

See full
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$705.48M+12.4%
Enterprise value$561.65M-12.6%
P/E12.1×-225×
P/S5.2×-4.9×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Revenue, net$39,663$25,881$75,883$46,282
Cost of product revenue (excluding $316 and $1,616 in intangible asset amortization for the three months ended June 30, 2026, and 2025, respectively, and $632 and $3,231 in intangible asset amortization for the six months ended June 30, 2026, and 2025, respectively, shown separately below)(1,525)(12,379)(3,422)(13,724)
Intangible asset amortization(316)(1,616)(632)(3,231)
Impairment of intangible assets(58,710)(58,710)
Gain on sale of future royalties, intellectual property, and other assets, net43,314
Operating expenses:
Research and development(4,486)(3,433)(8,878)(6,691)
Selling, general and administrative(16,559)(20,782)(37,342)(40,327)

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s total revenue?
Zevra Therapeutics, Inc. (ZVRA) reported total revenue of $39.66M in Q2 2026.
How has Zevra Therapeutics, Inc.'s total revenue changed year-over-year?
Zevra Therapeutics, Inc.'s total revenue increased by 53.3% year-over-year, from $25.88M to $39.66M.
What is the long-term trend for Zevra Therapeutics, Inc.'s total revenue?
Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s total revenue has grown at a 38.8% compound annual growth rate (CAGR), from $28.65M to $106.47M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Zevra Therapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude